INTRODUCTION
Cystic fibrosis (CF) is the most common lethal genetic disease among white populations, affecting approximately 70,000 persons worldwide. The leading cause of death is progressive lung disease, driven by a complex and diverse inflammatory immune syndrome induced by acute and chronic recurrent bacterial infections of the lung [1] [2] [3] .
The positive development of life expectancy in CF in recent years has led to a new discussion on evidence-based medicine, usefulness of therapy, burden of treatment and
health-related quality of life. In this discussion, dry powder antibiotic inhalation interventions such as the Colobreathe Ò inhaler play an important role and will be elucidated in this review.
Pulmonary exacerbations occur often in CF and are related to a decline in lung function [4] Therefore, controlling these exacerbations is a major target in CF treatment. Because of the high susceptibility of patients with CF to respiratory tract bacterial infections, oral, inhaled and intravenous antibiotic treatments are needed, and evidence-based treatments for Pseudomonas aeruginosa are already well established. In addition to P. aeruginosa, the bacteria most commonly believed to be pathogenic in CF include Staphylococcus aureus, Haemophilus influenzae, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia species, although evidence is low or does not exist [5] .
The treatment of the most common bacteria P. aeruginosa can be deviated into eradication therapy and suppression therapy. In the case of first-time cultivation of P. aeruginosa from a patient's throat swab or sputum, eradication of the pathogen is indicated. If a mucoid phenotype, a consequence of overproduction of exopolysaccharides alginate, is found in P. aeruginosa isolates from chronically infected patients with CF, eradication can no longer be the target of therapy [6] . The indications for eradication therapy of P. aeruginosa and the treatment of chronic pseudomonas infection are the major focus of inhaled antibiotic therapy. Currently approved drugs for inhalation therapy in patients with CF are tobramycin, colistimethate sodium, and aztreonam lysine [7] .
Eradication Therapy
In terms of eradication therapy, proof of P. aeruginosa colonization should be determined as early as possible in order to quickly begin inhaled antibiotic therapy to prevent the development of mucus-forming (mucoid) pseudomonas. The results for eradication of the non-mucoid P. aeruginosa are 81.2% on average, with a range of 63% to 100% [5] . For inhalation with tobramycin and colistin, data for eradication therapy are available in the literature.
The ELITE study [8] obtained similar results for the inhalation of tobramycin solution 300 mg twice daily for eradication therapy of 28 and 56 days. In both groups, the cultures were negative for P. aeruginosa 1 month after treatment in over 90% of the patients examined.
The addition of oral ciprofloxacin to nebulized tobramycin did not increase the eradication rate, as evidenced in the EPIC study [9] . Inhaled colistin in combination with ciprofloxacin also showed successful eradication results at a treatment duration of 3 months [10] . The comparison of inhaled therapy with colistin and oral ciprofloxacin for 3 months showed equal effectiveness of eradication therapy and therapy for 1 month with nebulized tobramycin [11] . Several different eradication treatment forms. therefore, appear promising. Most eradication treatments take place during childhood. Suppressive therapy in chronically colonized patients with CF seems to be a topic in adult patients.
AVAILABLE INHALED ANTIBIOTICS

Aminoglycosides
Aminoglycoside tobramycin was the first approved aerosol for inhaled antibiotic
, Novartis), and has therefore been used successfully for many years in patients with CF. The dose is 300 mg twice daily and is prescribed in so-called 4-week on/ off cycles. Patients inhale the drug for 4 weeks, followed by a 4-week break [12, 13, 14] . Another tobramycin inhalation solution is offered by the company Chiesi (Bramitob Ò ). With Bramitob Ò , similar to TOBI Ò , significant improvements in FEV1(%) were shown in the active treatment group compared to the placebo group [15] .
In addition, a recent US study showed reduced mortality in patients receiving inhaled tobramycin compared to the group without tobramycin inhalation (1.3% versus 2.1% at 2 years, 5.2% versus 8.0% at 5 years and 9.9% versus 15.0% after 10 years). In this study, 12,740 patients with CF were examined, of which 2538 had died. This once again underscores the importance of antibiotic inhalation as a major treatment option in CF [16] .
Monobactams
Aztreonam lysine is another inhaled antibiotic. [17] .
Colistimethate Sodium
The efficacy and safety of inhaled colistin was also demonstrated in several studies among patients with CF [18, 19, 20] . The efficacy and safety of the dry powder is discussed in this manuscript.
Dry Powder Inhalation
In was not taken into account [22] . The second dry powder antibiotic inhalation drug, Colobreathe Ò , which is approved in the EU but not in the US for chronic P. aeruginosa infections for patients with CF aged [6 years, will be discussed in this review.
The aim of this review is to discuss the efficacy, tolerability, pharmacokinetics and ease of use of the inhalation device and lung deposition of Colobreathe. (Table 1) . 
METHODS
SYSTEMIC ABSORPTION OF COLISTIMETHATE SODIUM DRY POWDER INHALATION
A multicenter, multiple-dose, open-label PK study in 34 patients with CF chronically infected with P. aeruginosa investigated the systemic absorption of inhaled colistimethate sodium dry powder in three age groups [33] . The maximum plasma concentration (C max ) for total colistimethate sodium was achieved between 0.5 and 1 h post-dose, with less than 350 ng/ml for the mean of the three age groups (children, adolescents, and adults; see also Fig. 2 ). The mean plasma C max for total colistimethate sodium and free colistin was significantly below the minimum inhibitory concentration (MIC) 90 against P. aeruginosa (4.0 lg/ml). The C max and AUC 0-6 for total colistimethate sodium and total free colistin were comparable between children and adolescents, while higher values were observed in the adult group. High PK variability (CV% ranged from 50.8% to 81.8% for the area under the curve [AUC] 0-6 and from 41.3% to 76.1% for C max ) was observed in all three age groups. The sputum results revealed a C max for total free colistin at least tenfold higher than the MIC 90 breakpoint for P. aeruginosa. Plasma levels of colistin were *500 times lower than documented levels following intravenous injection of colistimethate sodium [19] , suggesting a low risk of systemic toxicity and interactions with other drugs. The high levels of colistimethate sodium and colistin in sputum are consistent with the intended mechanism of the drug acting as a topical antibiotic for patients with chronic pseudomonas lung infection.
ANTIFUNGAL ACTIVITY OF COLOMYCIN
Recent in vitro data suggest that colistin may have fungicidal properties [34] , although the effect of colistin against Aspergillus in vivo is not known. In a retrospective comparison study of 76 patients with nebulized colistin, 30 patients with nebulized tobramycin and 28 patients without nebulized antibiotic therapy, results revealed that patients who did not receive Fig. 1 Colistimethate sodium deposited within whole lung Fig. 2 Mean total colistin methanesulfonate (CMS) and total free colistin in plasma across all age groups on day 8
inhaled antibiotics had significantly lower
Aspergillus-positive cultures in sputum samples (p = 0.003) and lower Aspergillus-specific IgE levels (p = 0.001) than patients inhaling an antibiotic drug. No significant difference was seen between the colistin and tobramycin groups aside from the colomycin group, which received less anti-fungal treatment (p = 0.03) [35] . The hypothesis that colistin has anti-fungal activity was prospectively analyzed by Schemuth et al. [36] . Their study demonstrated that in addition to its bactericidal activity, the antibiotic colistin also showed antifungal activity against respectively; p\0.001). However, clear and comparable data on acute exacerbations, a highly relevant outcome, are missing [37] . A similar range of adverse events was seen in both groups, except for cough, abnormal taste, and throat irritation, which were more frequent in the DPI group. Interestingly, these adverse events were observed only during the first 4 weeks of treatment, after which no difference in tolerability between formulations was seen [31, 38] . This observation is very important for the prescription of colistimethate sodium DPI and the expected adherence to the drug. Prescribers should focus their communication with patients not only on efficacy but also on side effects such as cough and on inhalation techniques. As economic strategies are becoming more important, this topic has been discussed in a review, although the authors conclude that thus far, there have been no data showing either a cost benefit or cost deficit for dry powder inhalation [39] .
RECOMMENDED CDPI INHALATION TECHNIQUES
The importance of communication to patients was mentioned in the previous chapter, but additional aspects must be added, as CF therapeutics now include a growing number of other dry powders (mannitol, TOBI Podhaler).
Therefore, education is crucial. Flume et al. [40] previously discussed this topic with regard to mannitol dry powder inhalation. Similar to their recommendations, we provide the most important points for colistimethate sodium dry powder inhalation via the Turbospin inhaler as follows:
1. The capsule should be inserted gently into the chamber with the widest end first, and should then be pierced by pushing the piston upwards until the visible line is reached. 2. Patients should inhale with the head tilted slightly upward, breathing in deeply at an even, steady rate sufficient to make the capsule spin.
3. The rotating capsule will make an audible ''rattle,'' indicating satisfactory inspiratory flow. 4. Rapid inhalation may result in cough, in which case the patient should slow their inhalation rate.
5. The capsule should be checked after inspiration, and if powder is still present, the patient should inhale a second time.
6. After taking in the dose, the patient should hold their breath for 10 s or for as long as it is comfortable, before breathing out slowly.
DRY POWDER IN THE ''REAL WORLD''
The FREEDOM study showed the efficacy of colistimethate sodium DPI in a phase III trial. [44] [45] [46] [47] [48] . As a consequence, the mean survival of patients with CF is steadily increasing and now exceeds 40 years of age in most European countries [49, 50] and beyond [51] . In this context, the burden of disease and especially the burden of treatment are of high interest because the aims in CF should include therapies, which are feasible in a growing CF population. Although new therapies targeting the CFTR defect will be implemented in the future, basic therapies such as vitamin and enzyme supplementation, anti-infective and anti-inflammatory therapies, physiotherapy, and bronchial clearance therapies will have to be continued. As inhalation therapy with antibiotics is usually a lifelong therapy, convenience and satisfaction with the therapy plays a major role. The ageing CF population and the high number of drugs, as well as time needed for CF therapy, will be positive factors supporting the use of dry powder inhalation such as colistimethate sodium or others. A longer duration of 
CONCLUSIONS
In this review, studies demonstrated no inferiority of CDPI to tobramycin inhalation solution in FEV1% predicted, and showed patient preference for the dry-powder inhalation of colistimethate sodium, as it is well tolerated, easier to use, less inconvenient and associated with improved adherence. 
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